Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (BRIGHT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05044871 |
|
Recruitment Status :
Not yet recruiting
First Posted : September 16, 2021
Last Update Posted : October 20, 2022
|
Sponsor:
Tongji Hospital
Collaborators:
Qilu Hospital of Shandong University
Hubei Cancer Hospital
Hunan Cancer Hospital
Peking University Cancer Hospital & Institute
Obstetrics and Gynecology Hospital of Zhejiang University
Sun Yat-sen University
Anhui Provincial Cancer Hospital
Jilin Provincial Tumor Hospital
First Affiliated Hospital, Sun Yat-Sen University
Affiliated Hospital of Jiangnan University
Information provided by (Responsible Party):
Qinglei Gao, Tongji Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Not yet recruiting |
|---|---|
| Estimated Primary Completion Date : | June 1, 2024 |
| Estimated Study Completion Date : | December 1, 2027 |